Key Highlights
- Pharmaceutical giant Eli Lilly is purchasing Centessa Pharmaceuticals at $38 per share in an all-cash transaction worth approximately $6.3 billion
- An additional contingent value right (CVR) worth about $9 per share could increase the acquisition value to roughly $7.8 billion
- Shares of Centessa trading in the U.S. soared 46% during premarket hours following the announcement
- The deal centers on Centessa’s sleep-wake disorder treatment portfolio
- Separately, Lilly revealed a $2.75 billion partnership with Insilico Medicine focused on AI-powered drug development
On Tuesday, Eli Lilly revealed plans to purchase Centessa Pharmaceuticals in a transaction valued at approximately $6.3 billion. The pharmaceutical company is offering $38 in cash for each share of the Frankfurt-based biotech firm.
Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion https://t.co/eB6KJtTmyv
— WSJ Business News (@WSJbusiness) March 31, 2026
The acquisition structure includes one non-transferrable contingent value right valued at around $9 per share. Should this CVR be triggered, the complete transaction value would climb to about $7.8 billion.
Shares of Centessa listed on U.S. exchanges jumped 46% in premarket activity after the deal was made public. The significant increase highlights the substantial premium Lilly is offering to secure Centessa’s sleep disorder drug portfolio.
Centessa Pharmaceuticals plc, CNTA
The transaction centers on treatments for sleep-wake disorders, representing a new therapeutic area for Lilly. Centessa offers a specialized development pipeline that Lilly expects can deliver commercial products.
This represents Lilly’s second significant transaction announced within 48 hours. The previous day, the pharmaceutical company unveiled a $2.75 billion collaboration with Insilico Medicine aimed at commercializing AI-developed therapeutics worldwide.
The Insilico partnership, which leverages artificial intelligence for drug candidate identification, demonstrates Lilly’s commitment to combining conventional pharmaceutical development with cutting-edge technology platforms.
Strategic Entry Into Sleep Disorder Market
The Centessa purchase represents a deliberate expansion into sleep-wake disorder therapeutics. This therapeutic segment has garnered increased interest from large pharmaceutical companies in recent years.
Centessa has been advancing orexin receptor agonists, a drug class that activates the brain’s awakening mechanisms. These compounds show promise for addressing conditions including narcolepsy and excessive daytime sleepiness.
Lilly’s decision to offer a substantial premium indicates strong confidence in the clinical promise of these programs. The CVR component ensures that portions of the total payment depend on achieving specific future development goals.
Artificial Intelligence Partnership Rounds Out Active Period
The Insilico collaboration announced Monday introduces another strategic element to Lilly’s recent dealmaking. Insilico employs artificial intelligence to engineer novel drug candidates, a methodology that may substantially reduce early development timelines.
Lilly indicated it will license and advance therapeutics identified through Insilico’s technology platform. Complete financial details beyond the $2.75 billion total have not been revealed.
Consecutive major announcements within a single day is uncommon even for a pharmaceutical company of Lilly’s scale. LLY shares traded approximately 1% higher Tuesday morning as the market digested both transactions.
Centessa’s Frankfurt-listed shares also rallied significantly following the news, with the cash offer positioned well above recent trading levels.
